Previous 10 | Next 10 |
Agency assigns PDUFA action date of May 8, 2023 MydCombi™, if approved, would be the first product incorporating Eyenovia’s novel Optejet ® drug delivery technology Company also announced receipt of California Medical Device Manufacturing license NEW...
Summary I will update the history I've had with Eyenovia. I will share with the reader the interim and pending events since my previous article. I will share my opinion on what I expect in the near future, and how they might invest in the company. For further d...
NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet ® delivery system for use both in combination with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progres...
NEW YORK, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet ® delivery system for use both in combination with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric p...
NEW YORK, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progre...
Eyenovia, Inc. (EYEN) Q3 2022 Earnings Conference Call November 10, 2022 04:30 PM ET Company Participants Eric Ribner - Investor Relations Michael Rowe - Chief Executive Officer John Gandolfo - Chief Financial Officer Conference Call Participants Leon...
Eyenovia press release ( NASDAQ: EYEN ): Q3 GAAP EPS of -$0.21. Ended the third quarter of 2022 with approximately $25.3 million in total cash and cash equivalents, including $7.9 million of restricted cash. For further details see: Eyenovia GAAP EPS of -$0.21
Announced positive results from the second Phase 3 study of MicroLine in presbyopia, VISION-2; Company planning to meet with the FDA to gain alignment on regulatory path forward as a drug/device combination product Company to host conference call and webcast today, November 10, at 4:3...
NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet ® delivery system for use both in combination with its own drug-device therapeutic programs as well as out-licensing for additional i...
NEW YORK, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet ® delivery system for use both in combination with its own drug-device therapeutic programs as well as out-licensing for additional i...
News, Short Squeeze, Breakout and More Instantly...
Collaboration to focus on the development of a formulation of Senju’s SJP-0035 for use with Eyenovia’s Optejet ® dispensing technology, following consultation with FDA Chronic dry eye estimated to be a $5 billion global addressable market NEW YORK, July 23, ...
Partnership co-promoting NovaBay’s Avenova ® Antimicrobial Lid & Lash Solution to large ophthalmic surgery centers along with one of Eyenovia’s FDA-approved product MydCombi™ Preparing for Eyenovia's launch of clobetasol propionate ophthalmic suspension, ...
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced today that it has entered into a securities purchase agreement with an institutional investor and its current large...